Literature DB >> 20515419

Prevalence and factors associated with renal dysfunction among HIV-infected patients.

Nancy Crum-Cianflone1, Anuradha Ganesan, Nimfa Teneza-Mora, Mark Riddle, Sheila Medina, Irma Barahona, Stephanie Brodine.   

Abstract

Renal dysfunction is an increasingly recognized non-AIDS-defining comorbidity among HIV-infected persons. The role of HIV-related factors in renal dysfunction remains unclear. We performed a cross-sectional study at two military clinics with open access to care to determine the impact of HIV factors, including antiretroviral therapy, on renal function. Renal dysfunction was defined as a glomerular filtration rate (GFR) < 60 mL/min/1.73 m(2). We evaluated 717 HIV patients with a median age of 41 years; 92% were male, 49% Caucasian, and 38% African American; median CD4 count was 515 cells/mm(3) and 73% were receiving highly active antiretroviral therapy (HAART). Twenty-two patients (3%) had renal dysfunction. Factors associated with renal dysfunction in the multivariate logistic analyses included older age (odds ratio [OR] 2.0 per 10 year increase, p = 0.006), lower CD4 nadir (OR 0.6 per 100 cell change, p = 0.02), and duration of tenofovir use (OR 1.5 per year use, p = 0.01). Among persons initiating tenofovir (n = 241), 50% experienced a reduction in GFR (median -10.5 mL/min/1.73 m(2), 95% CI, -8.9 to -13.3) within 2 years. Among tenofovir users, factors associated with a reduction in GFR included female gender (p < 0.001), African American ethnicity (p = 0.003), and lower CD4 nadir (p = 0.002). In summary, renal dysfunction was relatively uncommon among our HIV-infected patients, perhaps due to their young age, lack of comorbidities, or as a result of our definition that did not include proteinuria. Renal dysfunction was associated with duration of tenofovir use. Factors associated with renal loss among tenofovir users included female gender, African American ethnicity, and CD4 nadir <200 cells/mm(3). Consideration for more frequent monitoring of kidney function among these select HIV patients may be warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20515419      PMCID: PMC2933561          DOI: 10.1089/apc.2009.0326

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  36 in total

1.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech
Journal:  Clin Infect Dis       Date:  2005-04-22       Impact factor: 9.079

2.  Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

Authors:  Joel E Gallant; Michelle A Parish; Jeanne C Keruly; Richard D Moore
Journal:  Clin Infect Dis       Date:  2005-03-17       Impact factor: 9.079

3.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

4.  Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.

Authors:  A Winston; J Amin; Pwg Mallon; D Marriott; A Carr; D A Cooper; S Emery
Journal:  HIV Med       Date:  2006-03       Impact factor: 3.180

5.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

Review 6.  Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Authors:  Anthony E Zimmermann; Thomas Pizzoferrato; John Bedford; Anne Morris; Robert Hoffman; Gregory Braden
Journal:  Clin Infect Dis       Date:  2005-12-08       Impact factor: 9.079

7.  Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.

Authors:  Rachael Jones; Justin Stebbing; Mark Nelson; Graeme Moyle; Mark Bower; Sundhiya Mandalia; Brian Gazzard
Journal:  J Acquir Immune Defic Syndr       Date:  2004-12-01       Impact factor: 3.731

8.  Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.

Authors:  Elissa J Schwartz; Lynda A Szczech; Michael J Ross; Mary E Klotman; Jonathan A Winston; Paul E Klotman
Journal:  J Am Soc Nephrol       Date:  2005-06-29       Impact factor: 10.121

9.  Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Authors:  Hassane Izzedine; Jean Sebastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray
Journal:  Nephrol Dial Transplant       Date:  2005-03-01       Impact factor: 5.992

10.  Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.

Authors:  Samir K Gupta
Journal:  AIDS Patient Care STDS       Date:  2008-02       Impact factor: 5.078

View more
  26 in total

Review 1.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

2.  Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults.

Authors:  Amanda L Willig; Andrew O Westfall; E Turner Overton; Michael J Mugavero; Greer A Burkholder; David Kim; Eric Chamot; James L Raper; Heidi M Crane; Michael S Saag; James H Willig
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-23       Impact factor: 2.205

3.  Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection.

Authors:  Shikha Garg; Melanie Hoenig; Erika M Edwards; Caleb Bliss; Timothy Heeren; Sheila Tumilty; Alexander Y Walley; Margaret J Koziel; Paul R Skolnik; C Robert Horsburgh; Deborah Cotton
Journal:  AIDS Patient Care STDS       Date:  2011-02-10       Impact factor: 5.078

4.  Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA.

Authors:  Karen Ingrid Tasca; Vania V M Fagundes Vidal; Vanessa Martinez Manfio; Alexandre Naime Barbosa; Lenice do Rosario de Souza
Journal:  J Appl Biomed       Date:  2021-01-27       Impact factor: 1.797

5.  Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Authors:  Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

6.  Prevalence of renal disease within an urban HIV-infected cohort in northern Italy.

Authors:  Leonardo Calza; Elisa Vanino; Eleonora Magistrelli; Caterina Salvadori; Alessandra Cascavilla; Vincenzo Colangeli; Maria Assunta Di Bari; Roberto Manfredi; Pierluigi Viale
Journal:  Clin Exp Nephrol       Date:  2013-05-28       Impact factor: 2.801

Review 7.  Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.

Authors:  Fakhrul M Islam; Jianyun Wu; James Jansson; David P Wilson
Journal:  BMC Public Health       Date:  2012-03-23       Impact factor: 3.295

8.  Nephrotoxicity of HAART.

Authors:  Robert Kalyesubula; Mark A Perazella
Journal:  AIDS Res Treat       Date:  2011-08-15

9.  Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.

Authors:  Ying Cao; Yang Han; Jing Xie; Qu Cui; Lixia Zhang; Yijia Li; Yanling Li; Xiaojing Song; Ting Zhu; Taisheng Li
Journal:  BMC Infect Dis       Date:  2013-07-01       Impact factor: 3.090

10.  Renal Function Impairment and Associated Factors Among Adult HIV-Positive Patients Attending Antiretroviral Therapy Clinic in Mettu Karl Referral Hospital: Cross-Sectional Study.

Authors:  Bilisumamulifna Tefera Kefeni; Kifle Woldemichael Hajito; Masrie Getnet
Journal:  HIV AIDS (Auckl)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.